Mariana De Sa Tavares Russo

Mariana De Sa Tavares Russo

Auto-generated profile, based on publicly available information

Mariana De Sa Tavares Russo

McGill University 3 Rosalind & Morris Goodman Cancer Institute Montréal, Québec, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2021 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
YLYihang Li
Yihang Li
MPMaria F. Pazyra-Murphy
Maria F. Pazyra-Murphy
DADaina Avizonis
Daina Avizonis
MRMariana de Sá Tavares Russo
Mariana de Sá Tavares Russo
STSophia Tang
Sophia Tang
RSRosalind A. Segal
Rosalind A. Segal
Cancer patients frequently develop chemotherapy-induced peripheral neuropathy (CIPN), a painful and long-lasting disorder with profound somatosensory deficits. There are no effective therapies to prevent or treat this disorder. Pathologically, CIPN is characterized by a “dying-back” axonopathy that begins at intra-epidermal nerve terminals of sensory neurons and progresses in a retrograde fashion. Calcium dysregulation constitutes a critical event in CIPN, but it is not known how chemotherapies such as paclitaxel alter intra-axonal calcium and cause degeneration. Here, we demonstrate that paclitaxel triggers Sarm1-dependent cADPR production in distal axons, promoting intra-axonal calcium flux from both intracellular and extracellular calcium stores. Genetic or pharmacologic antagonists of cADPR signaling prevent paclitaxel-induced axon degeneration and allodynia symptoms, without mitigating the anti-neoplastic efficacy of paclitaxel. Our data demonstrate that cADPR is a calcium-modulating factor that promotes paclitaxel-induced axon degeneration and suggest that targeting cADPR signaling provides a potential therapeutic approach for treating paclitaxel-induced peripheral neuropathy (PIPN).

28 October 2026 in Cancer Research
Verified
Journal Article
Closed access
LPLucas Porras
Lucas Porras
MCMarina Carrière
Marina Carrière
AGAnn-Sophie Gironne
Ann-Sophie Gironne
HPHugo Philippeau
Hugo Philippeau
GAGabriel Alzial
Gabriel Alzial
GDGeneviève Deblois
Geneviève Deblois
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.

1 July 2026 in JCSM Communications
Verified
Journal Article
Open access
NBNeetika Bharaj
Neetika Bharaj
SHSarkis Hannaian
Sarkis Hannaian
JCJosé A. Correa
José A. Correa
MRMariana De Sa Tavares Russo
Mariana De Sa Tavares Russo
DADaina Avizonis
Daina Avizonis
TCTyler A. Churchward‐Venne
Tyler A. Churchward‐Venne
Background: (Pre)frail older adult patients undergoing cardiac surgery experience disproportionate mortality and prolonged length of stay, underpinned by low skeletal muscle mass (SMM), which is central to the underlying frailty pathophysiology. Conventional methods for assessing SMM have well‐recognized limitations in this population. The D 3 ‐creatine (D 3 ‐Cr) dilution method offers a non‐invasive, direct estimate of total‐body SMM. Pre‐surgery D 3 ‐Cr derived SMM and its relationship with strength, physical performance and multidimensional health status measures in (pre)frail older adult patients undergoing cardiac surgery have not been explored. Methods: Seventeen (pre)frail older adult patients (16 male, 1 female; median 75 [interquartile range: 67–75] years; body mass index 28.7 [24.2–29.9] kg/m 2 ; Clinical Frailty Scale 3 [3, 4]) ingested a single 30‐mg oral dose of D 3 ‐Cr 3.5 [3.0–4.3] days prior to scheduled elective or non‐emergent (inpatient) cardiac surgery. Spot urine was collected pre‐dose and 48–72 h post‐dose, and D 3 ‐creatinine (D 3 ‐Crn) and unlabelled creatine and creatinine were quantified by liquid chromatography–tandem mass spectrometry. Total‐body SMM was estimated using a published spillage‐correction algorithm; both a height‐adjusted and body weight–adjusted SMM index were calculated as SMM divided by height squared and SMM divided by body weight. Spearman's rank correlations (r s ) between strength, physical performance outcomes and multidimensional health status measures and (i) absolute SMM, (ii) height‐adjusted SMM index and (iii) body weight–adjusted SMM index were calculated; bias‐corrected and accelerated bootstrap (10 000 resamples) provided 95% confidence intervals (CIs). Kendall's τ was also calculated as a sensitivity analysis. Results: Median absolute total‐body SMM derived from D 3 ‐Cr dilution was 31.7 [27.4–40.9] kg, and the corresponding height‐adjusted and body weight–adjusted SMM index was 10.8 [9.7–13.7] and 41.7 [36.1–47.4]. Handgrip strength positively associated with absolute SMM, r s = 0.61 (95% CI [0.12, 0.91], n = 14, p = 0.02) and height‐adjusted SMM index, r s = 0.55 (95% CI [0.03, 0.88], n = 14, p = 0.04), but not body weight–adjusted SMM index. The 5× sit‐to‐stand, 4‐m gait speed, balance, Short Physical Performance Battery score, length of stay, SF‐36 physical functioning score and Mini Nutritional Assessment score were not significantly associated with absolute, height‐adjusted or body weight–adjusted SMM (all p ≥ 0.10). Conclusions: The D 3 ‐Cr dilution method can be applied for the pre‐operative assessment of SMM in (pre)frail older cardiac surgery patients. Handgrip strength tracked with both absolute and height‐adjusted D 3 ‐Cr derived SMM, providing preliminary support for an association between D 3 ‐Cr derived muscle mass and grip strength in older cardiac surgery patients.